S
SARTAR THERAPEUTICS OY
Sartar is a company dedicated to the development of targeted therapies for hard-to-treat cancers. Our experienced team is supported by key leading clinical ...
Country/Area ：Finland
Company Email ：info@sartartherapeutics.com
Company address ：Terkko Health Hub,Haartmaninkatu 4,00290 Helsinki,Finland
Company website ：*****
Company phone ：27546548
Established ：-
Main Products ：Rare diseases matter!Solution
Web Summary
Q1: What is the physical address of Sartar Therapeutics Oy?
A1: The physical address of Sartar Therapeutics Oy is Terkko Health Hub, Haartmaninkatu 4, Building 14, FI-00290 Helsinki, Finland.
Q2: What is the industry or sector in which Sartar Therapeutics Oy operates?
A2: Sartar Therapeutics Oy operates in the pharmaceutical and biotechnology industry, specifically in the development of targeted cancer therapies.
Q3: What is the company's focus or area of expertise?
A3: The company's focus is on the development of targeted cancer therapies, with a specific emphasis on gastrointestinal stromal tumors (GIST) and other rare cancers.
Q4: Who is the CEO of Sartar Therapeutics Oy?
A4: The CEO of Sartar Therapeutics Oy is Mikael Maksimow.
Q5: What is the email address of Sartar Therapeutics Oy's CEO?
A5: The email address of Sartar Therapeutics Oy's CEO, Mikael Maksimow, is firstname.lastname@sartartherapeutics.com.
Q6: What is the VAT ID number of Sartar Therapeutics Oy?
A6: The VAT ID number of Sartar Therapeutics Oy is FI27546548.
Q7: What is the company's location in relation to the University of Helsinki and the Helsinki University Hospital?
A7: The company is located at the Meilahti campus of the University of Helsinki, with the Helsinki University Hospital just across the street. This provides opportunities for collaboration with cancer research groups, key opinion leaders, and patient advocacy groups.
Q8: What is the significance of Sartar Therapeutics Oy's breakthrough discovery in cancer therapy?
A8: The company's breakthrough discovery involves exceptionally high phosphodiesterase 3A (PDE3A) gene expression in gastrointestinal stromal tumor (GIST), other soft tissue sarcoma subtypes, and subsets of other cancers. This represents a significant leap in cancer therapy and has led to the development of SAR003, a first-in-class targeted therapy for GIST.
Q9: What is SAR003 and how does it function?
A9: SAR003 is a breakthrough targeted therapy that functions as a molecular glue to induce cancer cell death in rapidly dividing cancer cells. It has shown outstanding efficacy in preclinical proof-of-concept data from sophisticated in vivo models.
Q10: What is the significance of Sartar Therapeutics Oy's involvement in international rare disease days and awareness campaigns?
A10: The company participates in international rare disease days, such as International Rare Disease Day and World Cancer Day, to raise awareness about the many rare disease types that collectively impact a significant number of patients worldwide. This includes rare cancers like soft tissue sarcomas, gastrointestinal stromal tumors (GIST), and other subtypes.
A1: The physical address of Sartar Therapeutics Oy is Terkko Health Hub, Haartmaninkatu 4, Building 14, FI-00290 Helsinki, Finland.
Q2: What is the industry or sector in which Sartar Therapeutics Oy operates?
A2: Sartar Therapeutics Oy operates in the pharmaceutical and biotechnology industry, specifically in the development of targeted cancer therapies.
Q3: What is the company's focus or area of expertise?
A3: The company's focus is on the development of targeted cancer therapies, with a specific emphasis on gastrointestinal stromal tumors (GIST) and other rare cancers.
Q4: Who is the CEO of Sartar Therapeutics Oy?
A4: The CEO of Sartar Therapeutics Oy is Mikael Maksimow.
Q5: What is the email address of Sartar Therapeutics Oy's CEO?
A5: The email address of Sartar Therapeutics Oy's CEO, Mikael Maksimow, is firstname.lastname@sartartherapeutics.com.
Q6: What is the VAT ID number of Sartar Therapeutics Oy?
A6: The VAT ID number of Sartar Therapeutics Oy is FI27546548.
Q7: What is the company's location in relation to the University of Helsinki and the Helsinki University Hospital?
A7: The company is located at the Meilahti campus of the University of Helsinki, with the Helsinki University Hospital just across the street. This provides opportunities for collaboration with cancer research groups, key opinion leaders, and patient advocacy groups.
Q8: What is the significance of Sartar Therapeutics Oy's breakthrough discovery in cancer therapy?
A8: The company's breakthrough discovery involves exceptionally high phosphodiesterase 3A (PDE3A) gene expression in gastrointestinal stromal tumor (GIST), other soft tissue sarcoma subtypes, and subsets of other cancers. This represents a significant leap in cancer therapy and has led to the development of SAR003, a first-in-class targeted therapy for GIST.
Q9: What is SAR003 and how does it function?
A9: SAR003 is a breakthrough targeted therapy that functions as a molecular glue to induce cancer cell death in rapidly dividing cancer cells. It has shown outstanding efficacy in preclinical proof-of-concept data from sophisticated in vivo models.
Q10: What is the significance of Sartar Therapeutics Oy's involvement in international rare disease days and awareness campaigns?
A10: The company participates in international rare disease days, such as International Rare Disease Day and World Cancer Day, to raise awareness about the many rare disease types that collectively impact a significant number of patients worldwide. This includes rare cancers like soft tissue sarcomas, gastrointestinal stromal tumors (GIST), and other subtypes.
Customs Data
As a purchaser
As a Supplier
Get the Whole details
Contact
Total found ??? Contacts
All
Boss
Management
Procurement
Other
Get the Whole details
